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Autosomal-dominant periodic fever with AA amyloidosis: Novel background, the mode of inheritance, a constellation
mutation in tumor necrosis factor receptor 1 gene. of clinical features, the nature of amyloid fibrils, and
Background. The recent identification of genes responsible ultimately the identification of the mutated gene.for syndromes of periodic fever with amyloidosis has opened
Until very recently, hereditary amyloidosis occurringthe way to a molecular diagnosis of hereditary AA amyloidosis.
in the context of periodic fever was only known to beMethods. A Belgian woman presented for genetic counsel-
ing. Three first-degree relatives had a diagnosis of renal amy- due to mutations in the Mediterranean fever (MEFV)
loidosis with a history of recurrent fever and inflammatory epi- gene [3, 4]. As familial Mediterranean fever (FMF) is
sodes. Medical records and pathological specimens were obtained
transmitted as an autosomal-recessive trait [3, 4], thefrom all physicians who had been in charge of her three rela-
autosomal-dominant form of amyloidosis following peri-tives. Immunohistochemical staining was performed on paraf-
fin-embedded material. A mutation search was performed in odic fever, reported in several families of European ori-
the MEFV (Mediterranean fever) and tumor necrosis factor gin, remained unexplained [5, 6].
receptor 1 (TNFR1 or TNFRSF1A) genes causing familial Med- In 1999, McDermott et al described seven families
iterranean fever (FMF) and tumor necrosis factor receptor-
affected by autosomal-dominant periodic fever, with am-associated periodic syndrome (TRAPS), respectively.
yloidosis in two of them. Six different missense mutationsResults. The family history was consistent with autosomal-
dominant transmission of periodic fever with arthralgias, ab- in TNFRSF1A, the gene encoding the tumor necrosis
dominal pain, and eventual AA amyloidosis involving the kid- factor (TNF) receptor 1 (also known as TNFR1 or p55)
neys, digestive tract, and thyroid. Recurrent amyloidosis in kidney were found, and the authors proposed the name ofgraft was demonstrated in one patient and was suspected in the
TRAPS (TNF Receptor-Associated Periodic Syndrome)other. A novel heterozygous mutation (C55S) in TNFRSF1A
was identified in the affected patient available for genetic test- for such mutations [7].
ing but not in the asymptomatic woman requiring counseling. In a Belgian family with autosomal-dominant AA am-
No mutation was detected in MEFV. yloidosis, we report a novel missense mutation (C55S)
Conclusions. We report a novel mutation (C55S) in
in TNFRSF1A. As illustrated in this family, recognitionTNFRSF1A, resulting in autosomal-dominant periodic fever
of the entity and identification of the mutation haveand AA amyloidosis. This condition, known as TRAPS, should be
added to the differential diagnosis of hereditary renal amyloidosis, implications for management of the disease and genetic
with obvious implications for management and genetic coun- counseling.
seling.
METHODSHereditary amyloidosis encompasses a wide range of
entities [1, 2]. The correct diagnosis is based on the ethnic Family study
Individual II-3 was seen at our outpatient nephrology
clinic. Her serum creatinine and urinalysis were normal.Key words: TNFR1, gene mutation, renal transplantation, inherited
kidney disease, familial Mediterranean fever, TRAPS, C55S mutation. She nevertheless wondered whether she was at risk of
transmitting to her potential lineage the renal amyloidosisReceived for publication October 10, 2000
that affected her father and two of her three siblings (Fig.and in revised form January 19, 2001
Accepted for publication January 23, 2001 1). Medical records of all affected family members were
obtained from the general practitioners, internists, andÓ 2001 by the International Society of Nephrology
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Mutation search in MEFV (GenBank accession
number Y14441)
The region of exon 10 between codons 663 and 771
(including the 4 most frequent mutations, namely, M680I,
M694 V, M694I, and V726A) was PCR amplified and
sequenced; the E148Q mutation in exon 2 was also
searched as described previously [10].
RESULTS
Clinical reports
Fig. 1. Pedigree of a Belgian family with autosomal-dominant periodic Patient II-1 was born in 1959. Since age four he has suf-
fever with AA amyloidosis. Shaded symbols indicate AA amyloidosis. fered from recurrent episodes of abdominal and/or back
Abbreviations are: P, C55S mutation; N, no C55S mutation; NT, no
pain and/or diarrhea and/or arthralgias with fever (upgenetic testing performed (patient I-1 died in 1985 and patient II-4
refused genetic testing). to 418C). These episodes lasted for up to four weeks.
Still’s disease was tentatively diagnosed, and steroids
were given intermittently from 1965, with some improve-
ment. In 1971, severe abdominal pain led to a laparot-
nephrologists who had previously been in charge of the omy, which failed to reveal any abnormality. In 1972,
three affected patients. Family members were contacted
proteinuria was noticed (1.8 g/L), and in 1973, a full-
and DNA testing was performed both in affected (II-1)
blown nephrotic syndrome developed. Recurrent febrile
and unaffected (I-2 and II-3) consenting individuals.
episodes and/or arthralgias partially responded to ste-
roids. In 1974, a kidney biopsy showed extensive glomer-Immunohistochemistry on pathological samples
ular (mesangial and arteriolar) amyloid deposits (Fig. 2A).In each affected patient, specimens of at least one organ
Azathioprine was added to steroids, with a poor toler-with amyloid deposits were obtained and reviewed by a
ance. It was replaced by chlorambucil, with a poor com-single experienced pathologist after appropriate staining.
pliance. Steroids were continued and transiently in-The diagnosis of amyloidosis rested on a positive
creased during bouts of abdominal pain or arthralgias.Congo Red staining, with typical birefringence under po-
In 1976, serum creatinine reached 2.3 mg/dL with a per-larized light. The typing of amyloid deposits rested on
sistent nephrotic syndrome. In February 1978, end-stageimmunoperoxydase staining using specific antisera against
renal failure with acute pericarditis required mainte-transthyretin (Dako, Glostrup, Denmark), k (Dako,
nance hemodialysis. On hemodialysis, attempts to with-Santa Barbara, CA, USA), and l light chains (Bioyeda,
draw steroids were followed by recurrent episodes ofRehovot, Israel) and serum amyloid A (SAA) protein
arthralgias, fever, and abdominal pain.(Calbiochem, La Jolla, CA, USA).
In 1979, a rectal biopsy revealed amyloid deposits. Echo-
cardiography and bone marrow examination were nor-Mutation search in TNFRSF1A (GenBank accession
mal. In July 1980, a cadaveric kidney transplantation (TP)number M75866)
was performed. Immunosuppressive regimen includedUsing standard procedures, genomic DNA was pre-
azathioprine and steroids. A single rejection episode waspared from peripheral blood lymphocytes [8]. Polymer-
successfully treated by intravenous methylprednisolone.ase chain reaction (PCR) amplification of exons 2, 3,
In 1987, gallstones prompted cholecystectomy. Patholog-and 4 of TNFRSF1A, encoding the two first extracellular
ical examination of the gallbladder showed amyloid de-cystein-rich domains (CRDs), was performed as pre-
posits. In 1992, serum bilirubin level rose to 7.2 mg/dL.viously described [9].
Liver biopsy showed veno-occlusive disease, but no amy-
Restriction analysis of the C55S mutation loid. Azathioprine was stopped, and cyclosporine was
started, with subsequent normalization of the bilirubinExon 3 of TNFRSF1A was PCR amplified in each
level. In 1993, total thyroidectomy was performed for amember of the family. The 220 bp amplified fragment
progressive large goiter. Pathological examination dis-was then digested with the Hinf I restriction enzyme
closed massive interstitial amyloidosis. In 1999, pro-(BioLabs, Beverly, MA, USA) according to the manu-
teinuria recurred (1.3 g/day). Graft biopsy showed glo-facturer’s instructions. Normal alleles displayed frag-
merular, interstitial, and arteriolar amyloid deposits.ments of 191 and 29 bp, whereas the C55S allele was
Treatment with colchicine (1 mg/day) was started.characterized by three fragments of 95, 96, and 29 bp
Patient II-4 was born in 1964. Since childhood, she com-(the 95 and 96 bp fragments comigrated on agarose gel
electrophoresis). plained of recurrent episodes of polyarthralgias and/or
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Fig. 2. Congo Red-positive amyloid, with ap-
ple-green birefringence under polarized light,
in mesangium and interlobular artery (A; 3200).
Strong staining of amyloid deposits with anti-
SAA antibody labeled with a peroxidase is
shown (B; 3400).
fever, lasting approximately 10 days. In 1985, proteinuria mal, but mild proteinuria (0.41 g/L) has recurred. Gastro-
duodenal biopsies show small amyloid deposits.developed (1.2 g/day); serum creatinine was normal. Kid-
ney biopsy showed mesangial amyloid deposits. Low- Patient I-1 was born in 1927. In the late 1960s, he
started to develop febrile episodes two to three timesdose colchicine was started. In 1988, the nephrotic syn-
drome developed, and in 1990, serum creatinine rose yearly, lasting approximately 10 days. These were incon-
stantly associated with cough and/or rhinorrhea and/orfrom 1.8 mg/dL to end-stage renal failure requiring he-
modialysis. At that time, a rectal biopsy failed to reveal back pain. In 1969, mild proteinuria was detected to-
gether with the acute-phase reaction (CRP1). He wasamyloid. While on hemodialysis, recurrent episodes of
otherwise unexplained fever and arthralgias developed, temporarily given steroids (10 mg prednisolone/day)
with clinical and biochemical improvement. In 1980, hetogether with biochemical signs of serum acute phase
reaction. In May 1994, a cadaveric kidney TP was per- developed arterial hypertension and the nephrotic syn-
drome. A left pleural rub was detected on physical exam-formed under cyclosporine, azathioprine, and low-dose
steroids. In 1998, a thyroidectomy was performed be- ination. Chest x-ray showed a right pleural effusion. Se-
rum creatinine was normal. The serum CRP level wascause of a progressive goiter. Massive interstitial amyloid
deposits were found. Currently, serum creatinine is nor- markedly elevated (111). A kidney biopsy showed
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massive amyloid deposition in glomeruli, tubules, and
interstitium, as well as in a few arterioles. A rectal biopsy
also showed amyloid in submucosal vessels. Symptom-
atic treatment was prescribed. He died suddenly in 1985.
At that time, serum creatinine was mildly elevated.
Immunohistochemistry on pathological samples
In all three patients with amyloidosis (I-1, II-1, II-4),
a review of pathological slides (I-1, kidney; II-1, native
kidney; II-4, thyroid) after appropriate immunohisto-
chemical staining showed that amyloid deposits stained
strongly with anti-SAA antibodies (Fig. 2B) but not with
anti-k, anti-l, and antitransthyretin antibodies.
Fig. 3. Detection of the TNFRSF1A mutation. Sequence analysis of
exon 3 in patient II-1 (A) compared with a control (B). The arrowDifferential diagnosis points to the G!C heterozygous mutation, which results in a cysteine-
to-serine substitution.The unequivocal demonstration of SAA protein in
amyloid deposits in this family excluded other forms of
autosomal-dominant amyloidosis caused by deposition
of different proteins (transthyretin, fibrinogen, lysozyme,
DISCUSSION
apolipoprotein A1, and gelsolin) [1, 2] and restricted the
The disease affecting this Belgian family associatesdifferential diagnosis to three hereditary disorders po-
periodic fever with eventual AA amyloidosis transmittedtentially complicated by AA amyloidosis: TRAPS (not
as an autosomal-dominant trait. Genetic testing dis-included in a comprehensive recent review of hereditary
closed a novel mutation (C55S) in the gene encodingamyloidosis [2]), FMF (infrequently transmitted as an
TNFRSF1A. Mutations in TNFRSF1A have very re-autosomal-dominant trait [11]), and finally the Muckle–
cently been shown to cause autosomal-dominant recur-Wells syndrome [12], characterized by recurrent urticar-
rent fever [7, 14], and the name TRAPS has been pro-ial rash and deafness (both absent in our patients) or
posed to include the genetically characterized clinicalthe closely related syndrome of autosomal-dominant
syndromes previously described as FMF-like syndromeperiodic fever with AA amyloidosis and urticarial le-
with amyloidosis, autosomal dominant periodic fever,sions without deafness described recently in an Indian
familial Hibernian fever, or familial periodic feverfamily [13].
[15–17].
Mutation search in TNFRSF1A Several features suggested a diagnosis of TRAPS
rather than FMF in this family. First, the autosomal dom-Mutation analysis of exons 2, 3, and 4 of TNFRSF1A
inant transmission strongly favored TRAPS [9, 14], al-coding the two N terminal CRDs was performed as de-
though pseudodominant or actual dominant transmis-scribed previously [9]. A heterozygous mutation was
sion of FMF with amyloidosis has been documentedidentified in exon 3 of patient II-1. This variant is a G!C
infrequently [11]. Second, attacks of fever often lastedtransversion that substitutes a serine for a cysteine at
weeks in our patients. This is suggestive of TRAPS ratherposition 55 (C55S; TGT!TCT; Fig. 3). This mutation
than FMF, in which attacks usually last at most threeC55S creates a Hinf I restriction site (data not shown).
days [14]. Again, this feature is not fully specific. Third,Individuals I-2 and II-3 had normal restriction patterns
attacks were apparently improved by steroids in our pa-electrophoresis. In order to rule out the possibility that
tients, an observation more compatible with TRAPSthis nucleotide substitution corresponds to a polymor-
than with FMF [14]. Finally, the family was not knownphism, PCR amplification of the TNFRSF1A exon 3 was
to have any Mediterranean ancestors. Mutations in theperformed on 100 alleles from unrelated French individ-
MEFV have, however, been found in some patients with-uals. The Hinf I restriction site was absent in all of them,
out Mediterranean ancestry [10].thus providing strong genetic evidence that this G!C
A third diagnostic possibility was the syndrome oftransversion was responsible for the disease.
autosomal-dominant periodic fever with AA amy-
Mutation search in MEFV loidosis described recently in an Indian family [13]. Inter-
estingly, this syndrome maps, like the Muckle–Wells syn-An FMF mutation search was done in patient II-1,
drome [12], to distal chromosome 1q; the gene(s)consisting of the sequencing of the hot-spot region lo-
responsible for both syndromes remains to be identified.cated in exon 10 of MEFV and the search for the E148Q
mutation in exon 2. No mutation was detected. Both syndromes share the existence of urticarial lesions,
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which were not observed in our patients, making this Interestingly, all hitherto reported TRAPS families
originate from Northern Europe (Scottish, Irish/Scottish,diagnosis less likely.
Overall, TRAPS appeared to be very likely, but only Irish, Finish, Irish/English/German, Irish, French/Cana-
dian, French, and now Belgian). As seven different muta-molecular studies could ascertain the diagnosis. A new
mutation (C55S) was detected in TNFRSF1A, while no tions have been identified in these eight families charac-
terized at the molecular level, a founder effect may bemutation was identified in MEFV.
In his seminal report on TRAPS, McDermott et al excluded. Thus, the complete absence of detection of
TRAPS in populations with other ethnic backgroundsstudied seven affected families and detected six different
missense mutations in the first two CRDs: CRD1 (C30R, may reflect underdiagnosis.
Making a diagnosis of TRAPS has implications for ap-C33Y, T50M, C52F) and CRD2 (C88R, C88Y) of the
TNFRSF1A [7]. An additional mutation in CRD1 (C30S) propriate management. A diagnosis of TRAPS may help
avoid invasive diagnostic procedures and ineffectivewas recently identified in a French family [9]. All identi-
fied mutations are at highly conserved positions in the therapies. For instance, in patient II-1, acute abdominal
pain prompted an exploratory laparotomy that provedTNF-receptor superfamily, and six out of seven (includ-
ing our new one) are expected to disrupt intramolecular negative, as has been reported in other TRAPS [15, 17]
or FMF families [4]. Because colchicine is ineffective indisulfide bonds. The CRD1 has been shown to be neces-
sary for the binding of TNF-a to TNFR1 [18]. The exact TRAPS [5, 9], patients II-1 and II-4 could be spared
this therapy. Of note, the reportedly favorable effect ofnature of the interaction between TNF-a and its recep-
tors remains to be elucidated. It has been hypothesized steroids in TRAPS [14] is challenged by our observation
of the relentless course of the disease after renal trans-that soluble forms of the receptors buffer the inflamma-
tory reaction by antagonizing the binding of TNF-a to plantation with a combination of steroids, cyclosporine
and azathioprine, as witnessed by the persistent acuteits membrane receptors and that a mutation in CRD im-
pairs the cleavage of the receptor to its soluble form [7]. phase reaction, recurrence of amyloidosis in kidney graft,
and progression of amyloidosis in other organs. This riskFurther progresses in the pathophysiology of TRAPS
may ultimately help unravel mechanisms of inflammation. of late-graft amyloidosis, however, should not deter the
nephrologist from considering TRAPS patients for renalA remarkable feature in our family is the development
of amyloidosis in all three affected subjects. Amyloidosis transplantation. The overall survival rate (and quality of
life) is indeed better in patients who have been trans-has indeed been reported in only two out of the seven
other families shown at the molecular level to be affected planted than in those put on the waiting list for a TP
but still being dialyzed [21].by TRAPS. Admittedly, other families with autosomal
dominant recurrent fever with amyloidosis have been Making a diagnosis of TRAPS has also implications
for genetic counseling. The absence of attacks of feverreported decades ago [5, 6]; however, whether they are
also affected by TRAPS or other unknown genetic dis- at age 38 in individual II-3 did not completely exclude
the carriage of TRAPS, as attacks of fever started aroundeases remains unknown. Interestingly, Cazeneuve et al
have recently demonstrated that a polymorphism in the the age of 40 in patient II-1, her father. In two other
TRAPS families, the age at onset of periodic fever variedSAA1 gene coding for the SAA1 protein isoform is an
independent risk factor for the development of AA amy- from less than 1 to 44 years and from 3 to 30 years, re-
spectively [9, 17]. In the latter family, a carrier of TRAPSloidosis in FMF [19]. Whether this finding applies to
TRAPS will require further investigation. was asymptomatic in his fourth decade [9]. Genetic test-
ing was therefore mandatory for definite reassurance ofAnother striking feature in our family was the severity
of amyloidosis. Both patients required hemodialysis fol- individual II-3. As another implication, genetic diagno-
sis is also advisable when a living-related kidney trans-lowed by renal transplantation, and several other organs
were subsequently affected by amyloidosis (thyroid in plantation is considered in such families.
Understanding the pathophysiology of TRAPS pavesboth cases, gastrointestinal tract in both cases, gallblad-
der in one), with an eventual recurrence of AA amy- the way for innovative treatments. As the disease is ap-
parently mediated by uncontrolled TNF activation, in-loidosis in the kidney graft in the patient with the longest
duration of symptomatic disease and suspected recur- hibitors of TNF could be of therapeutic value. Prelimi-
nary results with the use of etanercept [22], a TNFR:Fcrence in the other. Although progression of amyloid in-
volvement may reflect a peculiar amyloidogenic po- fusion protein, have been encouraging enough to launch
a trial with this agent [14].tential of this novel mutation, an alternative, more likely
explanation is that the extended life expectancy provided From a practical point of view, the clinician facing either
periodic fever with unexplained inflammatory symptomsby renal replacement therapy made the progression of
amyloidosis possible in the same way that visceral b2- or signs or unexplained AA amyloidosis should consider
not only FMF but also TRAPS. The latter diagnosis ismicroglobulin amyloidosis may eventually develop in he-
modialyzed patients years after articular involvement [20]. strongly suggested by an autosomal dominant transmis-
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